schliessen

Filtern

 

Bibliotheken

Absence of bilateral vision loss from amiodarone: A randomized trial

Amiodarone's role as a cause of toxic optic neuropathy is based on case reports. Annual frequency estimates of 0.36% to 2.0%, which have been made without reference to the dose or duration of treatment, are 12 to 200 times higher than those for idiopathic nonarteritic anterior ischemic neuropathy. T... Full description

Journal Title: American Heart Journal 2007, Vol.153(5), pp.837-842
Main Author: Mindel, Joel S
Other Authors: Anderson, Jill , Johnson, George , Hellkamp, Anne , Poole, Jeanne E , Mark, Daniel B , Lee, Kerry L , Bardy, Gust H
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0002-8703 ; E-ISSN: 1097-6744 ; DOI: 10.1016/j.ahj.2007.02.010
Link: https://www.sciencedirect.com/science/article/pii/S0002870307001433
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_ahj_2007_02_010
title: Absence of bilateral vision loss from amiodarone: A randomized trial
format: Article
creator:
  • Mindel, Joel S
  • Anderson, Jill
  • Johnson, George
  • Hellkamp, Anne
  • Poole, Jeanne E
  • Mark, Daniel B
  • Lee, Kerry L
  • Bardy, Gust H
subjects:
  • Medicine
ispartof: American Heart Journal, 2007, Vol.153(5), pp.837-842
description: Amiodarone's role as a cause of toxic optic neuropathy is based on case reports. Annual frequency estimates of 0.36% to 2.0%, which have been made without reference to the dose or duration of treatment, are 12 to 200 times higher than those for idiopathic nonarteritic anterior ischemic neuropathy. The object of this study was to determine the incidence, dose, and time until onset of bilateral vision loss from amiodarone as a secondary end point in an investigation of amiodarone's role in preventing sudden death. Randomized subjects received body weight–determined doses of closed-label amiodarone (n = 837) or placebo (n = 832) in a prospective double-masked manner. Closed-label amiodarone subjects were followed, unless death occurred, for a minimum of 27 months. Median follow-up in survivors was 45.5 months. The end point was removal from the study because of bilateral vision loss. No subject was removed from the study because of bilateral...
language: eng
source:
identifier: ISSN: 0002-8703 ; E-ISSN: 1097-6744 ; DOI: 10.1016/j.ahj.2007.02.010
fulltext: fulltext
issn:
  • 0002-8703
  • 00028703
  • 1097-6744
  • 10976744
url: Link


@attributes
ID107020142
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_ahj_2007_02_010
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_ahj_2007_02_010
sourcesystemPC
dbid
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94G.
107-5
118P~
129JM
13AABNK
14AAEDT
15AAKOC
16AAOAW
17AAQFI
18ABBQC
19ABFNM
20ABMZM
21ABYKQ
22ACDAQ
23ACRLP
24AEKER
25AEVXI
26AFKWA
27AFTJW
28AFXIZ
29AGHFR
30AGUBO
31AGYEJ
32AHHHB
33AIKHN
34AITUG
35AJBFU
36AJOXV
37AJRQY
38AJUYK
39AMFUW
40ANZVX
41BLXMC
42BNPGV
43EO8
44EO9
45EP2
46EP3
47FDB
48FGOYB
49FIRID
50FNPLU
51G-Q
52GBLVA
53HEB
54HMK
55HMO
56J1W
57KOM
58LCYCR
59OA.
60OAUVE
61OL~
62P-8
63P-9
64PC.
65Q38
66R2-
67RPZ
68SAE
69SDF
70SDG
71SDP
72SEL
73SES
74SEW
75SSH
76SSZ
77T5K
78UV1
79Z5R
80~G-
pqid1504609181
galeid162431665
display
typearticle
titleAbsence of bilateral vision loss from amiodarone: A randomized trial
creatorMindel, Joel S ; Anderson, Jill ; Johnson, George ; Hellkamp, Anne ; Poole, Jeanne E ; Mark, Daniel B ; Lee, Kerry L ; Bardy, Gust H
ispartofAmerican Heart Journal, 2007, Vol.153(5), pp.837-842
identifier
subjectMedicine
descriptionAmiodarone's role as a cause of toxic optic neuropathy is based on case reports. Annual frequency estimates of 0.36% to 2.0%, which have been made without reference to the dose or duration of treatment, are 12 to 200 times higher than those for idiopathic nonarteritic anterior ischemic neuropathy. The object of this study was to determine the incidence, dose, and time until onset of bilateral vision loss from amiodarone as a secondary end point in an investigation of amiodarone's role in preventing sudden death. Randomized subjects received body weight–determined doses of closed-label amiodarone (n = 837) or placebo (n = 832) in a prospective double-masked manner. Closed-label amiodarone subjects were followed, unless death occurred, for a minimum of 27 months. Median follow-up in survivors was 45.5 months. The end point was removal from the study because of bilateral vision loss. No subject was removed from the study because of bilateral...
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0002870307001433$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Mindel, Joel S
1Anderson, Jill
2Johnson, George
3Hellkamp, Anne
4Poole, Jeanne E
5Mark, Daniel B
6Lee, Kerry L
7Bardy, Gust H
titleAbsence of bilateral vision loss from amiodarone: A randomized trial
description

Amiodarone's role as a cause of toxic optic neuropathy is based on case reports. Annual frequency estimates of 0.36% to 2.0%, which have been made without reference to the dose or duration of treatment, are 12 to 200 times higher than those for idiopathic nonarteritic anterior ischemic neuropathy. The object of this study was to determine the incidence, dose, and time until onset of bilateral vision loss from amiodarone as a secondary end point in an investigation of amiodarone's role in preventing sudden death.

Randomized subjects received body weight–determined doses of closed-label amiodarone (n = 837) or placebo (n = 832) in a prospective double-masked manner. Closed-label amiodarone subjects were followed, unless death occurred, for a minimum of 27 months. Median follow-up in survivors was 45.5 months. The end point was removal from the study because of bilateral vision loss.

No subject was removed from the study because of bilateral...

subjectMedicine
general
0English
1Mosby, Inc
210.1016/j.ahj.2007.02.010
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_ahj_2007_02_010
issn
00002-8703
100028703
21097-6744
310976744
rsrctypearticle
creationdate2007
addtitleAmerican Heart Journal
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94G.
107-5
118P~
129JM
13AABNK
14AAEDT
15AAKOC
16AAOAW
17AAQFI
18ABBQC
19ABFNM
20ABMZM
21ABYKQ
22ACDAQ
23ACRLP
24AEKER
25AEVXI
26AFKWA
27AFTJW
28AFXIZ
29AGHFR
30AGUBO
31AGYEJ
32AHHHB
33AIKHN
34AITUG
35AJBFU
36AJOXV
37AJRQY
38AJUYK
39AMFUW
40ANZVX
41BLXMC
42BNPGV
43EO8
44EO9
45EP2
46EP3
47FDB
48FGOYB
49FIRID
50FNPLU
51G-Q
52GBLVA
53HEB
54HMK
55HMO
56J1W
57KOM
58LCYCR
59OA.
60OAUVE
61OL~
62P-8
63P-9
64PC.
65Q38
66R2-
67RPZ
68SAE
69SDF
70SDG
71SDP
72SEL
73SES
74SEW
75SSH
76SSZ
77T5K
78UV1
79Z5R
80~G-
startdate20070101
enddate20071231
lsr40American Heart Journal, 2007, Vol.153 (5), pp.837-842
doi10.1016/j.ahj.2007.02.010
citationpf 837 pt 842 vol 153 issue 5
lsr30VSR-Enriched:[pqid, galeid]
sort
titleAbsence of bilateral vision loss from amiodarone: A randomized trial
authorMindel, Joel S ; Anderson, Jill ; Johnson, George ; Hellkamp, Anne ; Poole, Jeanne E ; Mark, Daniel B ; Lee, Kerry L ; Bardy, Gust H
creationdate20070000
lso0120070000
facets
frbrgroupid4468804767553044942
frbrtype5
newrecords20190904
languageeng
topicMedicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Mindel, Joel S
1Anderson, Jill
2Johnson, George
3Hellkamp, Anne
4Poole, Jeanne E
5Mark, Daniel B
6Lee, Kerry L
7Bardy, Gust H
jtitleAmerican Heart Journal
creationdate2007
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Mindel
1Anderson
2Johnson
3Hellkamp
4Poole
5Mark
6Lee
7Bardy
aufirst
0Joel S
1Jill
2George
3Anne
4Jeanne E
5Daniel B
6Kerry L
7Gust H
auinitJ
auinit1J
au
0Mindel, Joel S
1Anderson, Jill
2Johnson, George
3Hellkamp, Anne
4Poole, Jeanne E
5Mark, Daniel B
6Lee, Kerry L
7Bardy, Gust H
atitleAbsence of bilateral vision loss from amiodarone: A randomized trial
jtitleAmerican Heart Journal
date2007
risdate2007
volume153
issue5
spage837
epage842
pages837-842
issn0002-8703
eissn1097-6744
formatjournal
genrearticle
ristypeJOUR
abstract

Amiodarone's role as a cause of toxic optic neuropathy is based on case reports. Annual frequency estimates of 0.36% to 2.0%, which have been made without reference to the dose or duration of treatment, are 12 to 200 times higher than those for idiopathic nonarteritic anterior ischemic neuropathy. The object of this study was to determine the incidence, dose, and time until onset of bilateral vision loss from amiodarone as a secondary end point in an investigation of amiodarone's role in preventing sudden death.

Randomized subjects received body weight–determined doses of closed-label amiodarone (n = 837) or placebo (n = 832) in a prospective double-masked manner. Closed-label amiodarone subjects were followed, unless death occurred, for a minimum of 27 months. Median follow-up in survivors was 45.5 months. The end point was removal from the study because of bilateral vision loss.

No subject was removed from the study because of bilateral...

pubMosby, Inc
doi10.1016/j.ahj.2007.02.010
lad01American Heart Journal